nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR1D—meninx—melanoma	0.0733	0.384	CbGeAlD
Methysergide—Leg edema—Temozolomide—melanoma	0.0164	0.0488	CcSEcCtD
Methysergide—HTR2A—hindlimb—melanoma	0.00866	0.0453	CbGeAlD
Methysergide—HTR1B—blood vessel—melanoma	0.0086	0.045	CbGeAlD
Methysergide—HTR1D—blood vessel—melanoma	0.00832	0.0436	CbGeAlD
Methysergide—HTR2A—appendage—melanoma	0.00743	0.0389	CbGeAlD
Methysergide—HTR7—endothelium—melanoma	0.00719	0.0376	CbGeAlD
Methysergide—Hyperaesthesia—Bleomycin—melanoma	0.00668	0.0198	CcSEcCtD
Methysergide—HTR7—blood vessel—melanoma	0.00663	0.0347	CbGeAlD
Methysergide—HTR1F—head—melanoma	0.00634	0.0332	CbGeAlD
Methysergide—Pain in extremity—Vemurafenib—melanoma	0.00628	0.0187	CcSEcCtD
Methysergide—Hyperaesthesia—Temozolomide—melanoma	0.00563	0.0167	CcSEcCtD
Methysergide—HTR1E—head—melanoma	0.00549	0.0287	CbGeAlD
Methysergide—Eosinophilia—Vemurafenib—melanoma	0.00537	0.016	CcSEcCtD
Methysergide—Weight decreased—Vemurafenib—melanoma	0.00491	0.0146	CcSEcCtD
Methysergide—HTR7—neck—melanoma	0.00474	0.0248	CbGeAlD
Methysergide—HTR2A—endothelium—melanoma	0.00448	0.0235	CbGeAlD
Methysergide—HTR1D—eye—melanoma	0.00443	0.0232	CbGeAlD
Methysergide—HTR6—head—melanoma	0.00431	0.0226	CbGeAlD
Methysergide—Oedema peripheral—Vemurafenib—melanoma	0.00428	0.0127	CcSEcCtD
Methysergide—Heartburn—Docetaxel—melanoma	0.00427	0.0127	CcSEcCtD
Methysergide—HTR2A—blood vessel—melanoma	0.00413	0.0216	CbGeAlD
Methysergide—SIGMAR1—eye—melanoma	0.00413	0.0216	CbGeAlD
Methysergide—Pleural effusion—Docetaxel—melanoma	0.00384	0.0114	CcSEcCtD
Methysergide—Alopecia—Vemurafenib—melanoma	0.00384	0.0114	CcSEcCtD
Methysergide—Thrombophlebitis—Carmustine—melanoma	0.00384	0.0114	CcSEcCtD
Methysergide—Thrombophlebitis—Temozolomide—melanoma	0.00371	0.011	CcSEcCtD
Methysergide—Back pain—Vemurafenib—melanoma	0.00366	0.0109	CcSEcCtD
Methysergide—HTR2B—skin of body—melanoma	0.00358	0.0188	CbGeAlD
Methysergide—SIGMAR1—mammalian vulva—melanoma	0.00328	0.0172	CbGeAlD
Methysergide—Arthralgia—Vemurafenib—melanoma	0.00322	0.00957	CcSEcCtD
Methysergide—Myalgia—Vemurafenib—melanoma	0.00322	0.00957	CcSEcCtD
Methysergide—Oliguria—Docetaxel—melanoma	0.00319	0.00948	CcSEcCtD
Methysergide—Ataxia—Carmustine—melanoma	0.00312	0.00928	CcSEcCtD
Methysergide—Ataxia—Temozolomide—melanoma	0.00302	0.00897	CcSEcCtD
Methysergide—Weight decreased—Bleomycin—melanoma	0.00297	0.00884	CcSEcCtD
Methysergide—HTR2A—neck—melanoma	0.00296	0.0155	CbGeAlD
Methysergide—Neutropenia—Dactinomycin—melanoma	0.00287	0.00852	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00281	0.00836	CcSEcCtD
Methysergide—Neutropenia—Carmustine—melanoma	0.00268	0.00798	CcSEcCtD
Methysergide—Gastrointestinal disorder—Vemurafenib—melanoma	0.00266	0.00792	CcSEcCtD
Methysergide—Fatigue—Vemurafenib—melanoma	0.00266	0.00791	CcSEcCtD
Methysergide—Constipation—Vemurafenib—melanoma	0.00264	0.00784	CcSEcCtD
Methysergide—Lightheadedness—Docetaxel—melanoma	0.00263	0.00782	CcSEcCtD
Methysergide—HTR1B—head—melanoma	0.0026	0.0136	CbGeAlD
Methysergide—Neutropenia—Temozolomide—melanoma	0.00259	0.00771	CcSEcCtD
Methysergide—Dysuria—Temozolomide—melanoma	0.00259	0.00771	CcSEcCtD
Methysergide—Weight increased—Temozolomide—melanoma	0.00252	0.0075	CcSEcCtD
Methysergide—HTR1D—head—melanoma	0.00251	0.0132	CbGeAlD
Methysergide—Weight decreased—Temozolomide—melanoma	0.00251	0.00746	CcSEcCtD
Methysergide—HTR2C—head—melanoma	0.00249	0.013	CbGeAlD
Methysergide—Thrombophlebitis—Docetaxel—melanoma	0.00247	0.00733	CcSEcCtD
Methysergide—Flushing—Bleomycin—melanoma	0.00244	0.00726	CcSEcCtD
Methysergide—Body temperature increased—Vemurafenib—melanoma	0.00244	0.00725	CcSEcCtD
Methysergide—HTR2B—head—melanoma	0.00234	0.0122	CbGeAlD
Methysergide—Alopecia—Bleomycin—melanoma	0.00233	0.00691	CcSEcCtD
Methysergide—Flushing—Dactinomycin—melanoma	0.00228	0.00677	CcSEcCtD
Methysergide—Oedema peripheral—Carmustine—melanoma	0.00226	0.00672	CcSEcCtD
Methysergide—Asthenia—Vemurafenib—melanoma	0.00221	0.00658	CcSEcCtD
Methysergide—HTR2A—eye—melanoma	0.0022	0.0115	CbGeAlD
Methysergide—Oedema peripheral—Temozolomide—melanoma	0.00219	0.0065	CcSEcCtD
Methysergide—HTR2A—retina—melanoma	0.00218	0.0114	CbGeAlD
Methysergide—Alopecia—Dactinomycin—melanoma	0.00217	0.00645	CcSEcCtD
Methysergide—Pain in extremity—Docetaxel—melanoma	0.00213	0.00634	CcSEcCtD
Methysergide—Flushing—Carmustine—melanoma	0.00213	0.00634	CcSEcCtD
Methysergide—Ill-defined disorder—Bleomycin—melanoma	0.00213	0.00632	CcSEcCtD
Methysergide—Diarrhoea—Vemurafenib—melanoma	0.00211	0.00627	CcSEcCtD
Methysergide—HTR1A—head—melanoma	0.0021	0.011	CbGeAlD
Methysergide—Malaise—Bleomycin—melanoma	0.00207	0.00614	CcSEcCtD
Methysergide—Flushing—Temozolomide—melanoma	0.00206	0.00612	CcSEcCtD
Methysergide—Dizziness—Vemurafenib—melanoma	0.00204	0.00606	CcSEcCtD
Methysergide—Alopecia—Carmustine—melanoma	0.00203	0.00603	CcSEcCtD
Methysergide—Ataxia—Docetaxel—melanoma	0.00201	0.00596	CcSEcCtD
Methysergide—HTR7—head—melanoma	0.002	0.0105	CbGeAlD
Methysergide—Ill-defined disorder—Dactinomycin—melanoma	0.00198	0.00589	CcSEcCtD
Methysergide—Vomiting—Vemurafenib—melanoma	0.00196	0.00583	CcSEcCtD
Methysergide—Alopecia—Temozolomide—melanoma	0.00196	0.00583	CcSEcCtD
Methysergide—Chest pain—Bleomycin—melanoma	0.00195	0.0058	CcSEcCtD
Methysergide—Myalgia—Bleomycin—melanoma	0.00195	0.0058	CcSEcCtD
Methysergide—Orthostatic hypotension—Docetaxel—melanoma	0.00195	0.00579	CcSEcCtD
Methysergide—Rash—Vemurafenib—melanoma	0.00195	0.00578	CcSEcCtD
Methysergide—Dermatitis—Vemurafenib—melanoma	0.00194	0.00578	CcSEcCtD
Methysergide—Back pain—Carmustine—melanoma	0.00193	0.00575	CcSEcCtD
Methysergide—Discomfort—Bleomycin—melanoma	0.00193	0.00573	CcSEcCtD
Methysergide—Malaise—Dactinomycin—melanoma	0.00193	0.00573	CcSEcCtD
Methysergide—Oedema—Bleomycin—melanoma	0.00187	0.00556	CcSEcCtD
Methysergide—Back pain—Temozolomide—melanoma	0.00187	0.00555	CcSEcCtD
Methysergide—Nausea—Vemurafenib—melanoma	0.00183	0.00545	CcSEcCtD
Methysergide—Thrombocytopenia—Bleomycin—melanoma	0.00183	0.00544	CcSEcCtD
Methysergide—Myalgia—Dactinomycin—melanoma	0.00182	0.00541	CcSEcCtD
Methysergide—Discomfort—Dactinomycin—melanoma	0.0018	0.00534	CcSEcCtD
Methysergide—Ill-defined disorder—Temozolomide—melanoma	0.00179	0.00533	CcSEcCtD
Methysergide—Oedema—Dactinomycin—melanoma	0.00174	0.00518	CcSEcCtD
Methysergide—Malaise—Temozolomide—melanoma	0.00174	0.00518	CcSEcCtD
Methysergide—Convulsion—Carmustine—melanoma	0.00173	0.00515	CcSEcCtD
Methysergide—Neutropenia—Docetaxel—melanoma	0.00172	0.00513	CcSEcCtD
Methysergide—Thrombocytopenia—Dactinomycin—melanoma	0.00171	0.00507	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Bleomycin—melanoma	0.0017	0.00506	CcSEcCtD
Methysergide—Myalgia—Carmustine—melanoma	0.0017	0.00506	CcSEcCtD
Methysergide—Chest pain—Carmustine—melanoma	0.0017	0.00506	CcSEcCtD
Methysergide—Paraesthesia—Bleomycin—melanoma	0.00168	0.00499	CcSEcCtD
Methysergide—Weight increased—Docetaxel—melanoma	0.00168	0.00499	CcSEcCtD
Methysergide—Convulsion—Temozolomide—melanoma	0.00167	0.00498	CcSEcCtD
Methysergide—Weight decreased—Docetaxel—melanoma	0.00167	0.00496	CcSEcCtD
Methysergide—Dyspnoea—Bleomycin—melanoma	0.00167	0.00495	CcSEcCtD
Methysergide—Arthralgia—Temozolomide—melanoma	0.00165	0.00489	CcSEcCtD
Methysergide—Myalgia—Temozolomide—melanoma	0.00165	0.00489	CcSEcCtD
Methysergide—SIGMAR1—lymph node—melanoma	0.00164	0.00859	CbGeAlD
Methysergide—HTR2B—lymph node—melanoma	0.00164	0.00857	CbGeAlD
Methysergide—Oedema—Carmustine—melanoma	0.00163	0.00485	CcSEcCtD
Methysergide—Discomfort—Temozolomide—melanoma	0.00163	0.00483	CcSEcCtD
Methysergide—Pain—Bleomycin—melanoma	0.0016	0.00475	CcSEcCtD
Methysergide—Thrombocytopenia—Carmustine—melanoma	0.0016	0.00475	CcSEcCtD
Methysergide—Tachycardia—Carmustine—melanoma	0.00159	0.00473	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00159	0.00472	CcSEcCtD
Methysergide—Oedema—Temozolomide—melanoma	0.00158	0.00469	CcSEcCtD
Methysergide—Thrombocytopenia—Temozolomide—melanoma	0.00154	0.00459	CcSEcCtD
Methysergide—Feeling abnormal—Bleomycin—melanoma	0.00154	0.00458	CcSEcCtD
Methysergide—Fatigue—Dactinomycin—melanoma	0.0015	0.00447	CcSEcCtD
Methysergide—Pain—Dactinomycin—melanoma	0.00149	0.00443	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Carmustine—melanoma	0.00149	0.00442	CcSEcCtD
Methysergide—Body temperature increased—Bleomycin—melanoma	0.00148	0.00439	CcSEcCtD
Methysergide—Insomnia—Carmustine—melanoma	0.00148	0.00439	CcSEcCtD
Methysergide—Paraesthesia—Carmustine—melanoma	0.00147	0.00436	CcSEcCtD
Methysergide—Dyspnoea—Carmustine—melanoma	0.00146	0.00432	CcSEcCtD
Methysergide—Oedema peripheral—Docetaxel—melanoma	0.00145	0.00432	CcSEcCtD
Methysergide—Somnolence—Carmustine—melanoma	0.00145	0.00431	CcSEcCtD
Methysergide—Feeling abnormal—Dactinomycin—melanoma	0.00144	0.00427	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Temozolomide—melanoma	0.00144	0.00427	CcSEcCtD
Methysergide—Insomnia—Temozolomide—melanoma	0.00143	0.00424	CcSEcCtD
Methysergide—Gastrointestinal pain—Dactinomycin—melanoma	0.00143	0.00424	CcSEcCtD
Methysergide—Paraesthesia—Temozolomide—melanoma	0.00142	0.00421	CcSEcCtD
Methysergide—Gastrointestinal disorder—Carmustine—melanoma	0.00141	0.00419	CcSEcCtD
Methysergide—Dyspnoea—Temozolomide—melanoma	0.00141	0.00418	CcSEcCtD
Methysergide—Somnolence—Temozolomide—melanoma	0.0014	0.00417	CcSEcCtD
Methysergide—Pain—Carmustine—melanoma	0.0014	0.00415	CcSEcCtD
Methysergide—Constipation—Carmustine—melanoma	0.0014	0.00415	CcSEcCtD
Methysergide—Dyspepsia—Temozolomide—melanoma	0.00139	0.00413	CcSEcCtD
Methysergide—Abdominal pain—Dactinomycin—melanoma	0.00138	0.0041	CcSEcCtD
Methysergide—Body temperature increased—Dactinomycin—melanoma	0.00138	0.0041	CcSEcCtD
Methysergide—Flushing—Docetaxel—melanoma	0.00137	0.00407	CcSEcCtD
Methysergide—Gastrointestinal disorder—Temozolomide—melanoma	0.00136	0.00405	CcSEcCtD
Methysergide—Fatigue—Temozolomide—melanoma	0.00136	0.00404	CcSEcCtD
Methysergide—Pain—Temozolomide—melanoma	0.00135	0.00401	CcSEcCtD
Methysergide—Constipation—Temozolomide—melanoma	0.00135	0.00401	CcSEcCtD
Methysergide—Feeling abnormal—Carmustine—melanoma	0.00135	0.004	CcSEcCtD
Methysergide—Asthenia—Bleomycin—melanoma	0.00134	0.00399	CcSEcCtD
Methysergide—Gastrointestinal pain—Carmustine—melanoma	0.00133	0.00397	CcSEcCtD
Methysergide—Alopecia—Docetaxel—melanoma	0.0013	0.00388	CcSEcCtD
Methysergide—Feeling abnormal—Temozolomide—melanoma	0.0013	0.00386	CcSEcCtD
Methysergide—Body temperature increased—Carmustine—melanoma	0.00129	0.00383	CcSEcCtD
Methysergide—Abdominal pain—Carmustine—melanoma	0.00129	0.00383	CcSEcCtD
Methysergide—Gastrointestinal pain—Temozolomide—melanoma	0.00129	0.00383	CcSEcCtD
Methysergide—Asthenia—Dactinomycin—melanoma	0.00125	0.00372	CcSEcCtD
Methysergide—HTR2A—head—melanoma	0.00125	0.00654	CbGeAlD
Methysergide—Abdominal pain—Temozolomide—melanoma	0.00125	0.00371	CcSEcCtD
Methysergide—Body temperature increased—Temozolomide—melanoma	0.00125	0.00371	CcSEcCtD
Methysergide—Back pain—Docetaxel—melanoma	0.00124	0.00369	CcSEcCtD
Methysergide—Diarrhoea—Dactinomycin—melanoma	0.00119	0.00355	CcSEcCtD
Methysergide—Vomiting—Bleomycin—melanoma	0.00119	0.00353	CcSEcCtD
Methysergide—Rash—Bleomycin—melanoma	0.00118	0.0035	CcSEcCtD
Methysergide—Dermatitis—Bleomycin—melanoma	0.00118	0.0035	CcSEcCtD
Methysergide—Asthenia—Carmustine—melanoma	0.00117	0.00348	CcSEcCtD
Methysergide—Asthenia—Temozolomide—melanoma	0.00113	0.00336	CcSEcCtD
Methysergide—Diarrhoea—Carmustine—melanoma	0.00112	0.00332	CcSEcCtD
Methysergide—Convulsion—Docetaxel—melanoma	0.00111	0.00331	CcSEcCtD
Methysergide—Nausea—Bleomycin—melanoma	0.00111	0.0033	CcSEcCtD
Methysergide—Vomiting—Dactinomycin—melanoma	0.00111	0.00329	CcSEcCtD
Methysergide—Rash—Dactinomycin—melanoma	0.0011	0.00327	CcSEcCtD
Methysergide—Arthralgia—Docetaxel—melanoma	0.00109	0.00325	CcSEcCtD
Methysergide—Chest pain—Docetaxel—melanoma	0.00109	0.00325	CcSEcCtD
Methysergide—Myalgia—Docetaxel—melanoma	0.00109	0.00325	CcSEcCtD
Methysergide—Dizziness—Carmustine—melanoma	0.00108	0.00321	CcSEcCtD
Methysergide—Diarrhoea—Temozolomide—melanoma	0.00108	0.00321	CcSEcCtD
Methysergide—Oedema—Docetaxel—melanoma	0.00105	0.00312	CcSEcCtD
Methysergide—Dizziness—Temozolomide—melanoma	0.00104	0.0031	CcSEcCtD
Methysergide—Vomiting—Carmustine—melanoma	0.00104	0.00308	CcSEcCtD
Methysergide—Nausea—Dactinomycin—melanoma	0.00104	0.00308	CcSEcCtD
Methysergide—Rash—Carmustine—melanoma	0.00103	0.00306	CcSEcCtD
Methysergide—Dermatitis—Carmustine—melanoma	0.00103	0.00306	CcSEcCtD
Methysergide—Thrombocytopenia—Docetaxel—melanoma	0.00103	0.00305	CcSEcCtD
Methysergide—Tachycardia—Docetaxel—melanoma	0.00102	0.00304	CcSEcCtD
Methysergide—Vomiting—Temozolomide—melanoma	0.001	0.00298	CcSEcCtD
Methysergide—Rash—Temozolomide—melanoma	0.000995	0.00296	CcSEcCtD
Methysergide—Dermatitis—Temozolomide—melanoma	0.000994	0.00295	CcSEcCtD
Methysergide—Nausea—Carmustine—melanoma	0.00097	0.00288	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Docetaxel—melanoma	0.000956	0.00284	CcSEcCtD
Methysergide—Insomnia—Docetaxel—melanoma	0.000949	0.00282	CcSEcCtD
Methysergide—Paraesthesia—Docetaxel—melanoma	0.000942	0.0028	CcSEcCtD
Methysergide—Nausea—Temozolomide—melanoma	0.000937	0.00278	CcSEcCtD
Methysergide—Dyspnoea—Docetaxel—melanoma	0.000935	0.00278	CcSEcCtD
Methysergide—Somnolence—Docetaxel—melanoma	0.000933	0.00277	CcSEcCtD
Methysergide—Dyspepsia—Docetaxel—melanoma	0.000923	0.00274	CcSEcCtD
Methysergide—Gastrointestinal disorder—Docetaxel—melanoma	0.000906	0.00269	CcSEcCtD
Methysergide—Fatigue—Docetaxel—melanoma	0.000904	0.00269	CcSEcCtD
Methysergide—Constipation—Docetaxel—melanoma	0.000897	0.00267	CcSEcCtD
Methysergide—Pain—Docetaxel—melanoma	0.000897	0.00267	CcSEcCtD
Methysergide—Feeling abnormal—Docetaxel—melanoma	0.000864	0.00257	CcSEcCtD
Methysergide—Gastrointestinal pain—Docetaxel—melanoma	0.000858	0.00255	CcSEcCtD
Methysergide—Abdominal pain—Docetaxel—melanoma	0.000829	0.00246	CcSEcCtD
Methysergide—Body temperature increased—Docetaxel—melanoma	0.000829	0.00246	CcSEcCtD
Methysergide—Asthenia—Docetaxel—melanoma	0.000753	0.00224	CcSEcCtD
Methysergide—Diarrhoea—Docetaxel—melanoma	0.000718	0.00213	CcSEcCtD
Methysergide—Dizziness—Docetaxel—melanoma	0.000694	0.00206	CcSEcCtD
Methysergide—Vomiting—Docetaxel—melanoma	0.000667	0.00198	CcSEcCtD
Methysergide—Rash—Docetaxel—melanoma	0.000661	0.00197	CcSEcCtD
Methysergide—Dermatitis—Docetaxel—melanoma	0.000661	0.00196	CcSEcCtD
Methysergide—Nausea—Docetaxel—melanoma	0.000623	0.00185	CcSEcCtD
Methysergide—Ergonovine—ABCB1—melanoma	0.000515	0.475	CrCbGaD
Methysergide—Ergotamine—ABCB1—melanoma	0.00029	0.267	CrCbGaD
Methysergide—Bromocriptine—ABCB1—melanoma	0.00028	0.258	CrCbGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—melanoma	2.86e-05	6.06e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—melanoma	2.85e-05	6.06e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KDR—melanoma	2.85e-05	6.05e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—melanoma	2.84e-05	6.03e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—melanoma	2.84e-05	6.02e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—melanoma	2.82e-05	5.98e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—melanoma	2.82e-05	5.97e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—melanoma	2.81e-05	5.97e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2—melanoma	2.81e-05	5.96e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—melanoma	2.81e-05	5.96e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—melanoma	2.8e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—melanoma	2.8e-05	5.93e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CTNNB1—melanoma	2.79e-05	5.92e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CTNNB1—melanoma	2.79e-05	5.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IGF1—melanoma	2.78e-05	5.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—MAPK1—melanoma	2.77e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—melanoma	2.77e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IGF1—melanoma	2.77e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CTNNB1—melanoma	2.77e-05	5.88e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—melanoma	2.76e-05	5.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—MAPK1—melanoma	2.76e-05	5.85e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—melanoma	2.76e-05	5.85e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—melanoma	2.76e-05	5.84e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FN1—melanoma	2.75e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—melanoma	2.74e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—melanoma	2.74e-05	5.81e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—melanoma	2.74e-05	5.8e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—melanoma	2.73e-05	5.8e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CDKN1A—melanoma	2.73e-05	5.78e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CDKN1A—melanoma	2.72e-05	5.78e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—melanoma	2.72e-05	5.77e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—melanoma	2.72e-05	5.77e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—melanoma	2.72e-05	5.76e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—melanoma	2.72e-05	5.76e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CTNNB1—melanoma	2.71e-05	5.75e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NFKB1—melanoma	2.71e-05	5.74e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CDKN1A—melanoma	2.71e-05	5.74e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NFKB1—melanoma	2.7e-05	5.74e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—melanoma	2.7e-05	5.73e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1B—melanoma	2.7e-05	5.72e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAP2K1—melanoma	2.69e-05	5.71e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NFKB1—melanoma	2.69e-05	5.7e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOTCH1—melanoma	2.69e-05	5.7e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAP2K1—melanoma	2.68e-05	5.68e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—melanoma	2.67e-05	5.67e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—melanoma	2.67e-05	5.66e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—melanoma	2.66e-05	5.64e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—melanoma	2.66e-05	5.64e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—melanoma	2.65e-05	5.63e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—melanoma	2.65e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDKN1A—melanoma	2.65e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	2.65e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—melanoma	2.64e-05	5.61e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—melanoma	2.64e-05	5.61e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2—melanoma	2.64e-05	5.6e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—melanoma	2.64e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—melanoma	2.63e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—melanoma	2.63e-05	5.59e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CD80—melanoma	2.63e-05	5.58e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NFKB1—melanoma	2.63e-05	5.58e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—melanoma	2.63e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KIT—melanoma	2.63e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APC—melanoma	2.63e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—melanoma	2.63e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—melanoma	2.63e-05	5.57e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—melanoma	2.62e-05	5.55e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—melanoma	2.6e-05	5.52e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—melanoma	2.6e-05	5.51e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGF—melanoma	2.6e-05	5.51e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—melanoma	2.58e-05	5.47e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—melanoma	2.57e-05	5.46e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FGF2—melanoma	2.56e-05	5.43e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CTNNB1—melanoma	2.55e-05	5.4e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FGF2—melanoma	2.55e-05	5.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MAPK3—melanoma	2.52e-05	5.34e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—melanoma	2.5e-05	5.3e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1A—melanoma	2.49e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—melanoma	2.49e-05	5.28e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—melanoma	2.48e-05	5.27e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NFKB1—melanoma	2.47e-05	5.24e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—melanoma	2.47e-05	5.24e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—melanoma	2.46e-05	5.21e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—melanoma	2.45e-05	5.21e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—melanoma	2.44e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—melanoma	2.43e-05	5.16e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—melanoma	2.43e-05	5.16e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—melanoma	2.43e-05	5.15e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—melanoma	2.43e-05	5.15e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—melanoma	2.42e-05	5.14e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—melanoma	2.42e-05	5.14e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—melanoma	2.41e-05	5.12e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—melanoma	2.41e-05	5.11e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1—melanoma	2.41e-05	5.1e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—melanoma	2.4e-05	5.1e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—melanoma	2.4e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MAPK1—melanoma	2.39e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—melanoma	2.39e-05	5.08e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—melanoma	2.39e-05	5.07e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—melanoma	2.39e-05	5.06e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—melanoma	2.38e-05	5.05e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—melanoma	2.36e-05	5.01e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ERBB2—melanoma	2.36e-05	5.01e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—melanoma	2.36e-05	5e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ERBB2—melanoma	2.35e-05	4.98e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—melanoma	2.33e-05	4.94e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAP2K1—melanoma	2.32e-05	4.93e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK3—melanoma	2.32e-05	4.93e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK3—melanoma	2.32e-05	4.92e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—melanoma	2.32e-05	4.92e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—melanoma	2.31e-05	4.9e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK3—melanoma	2.31e-05	4.89e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—melanoma	2.29e-05	4.87e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	2.29e-05	4.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—melanoma	2.26e-05	4.8e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—melanoma	2.26e-05	4.8e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK3—melanoma	2.26e-05	4.79e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—melanoma	2.26e-05	4.79e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—melanoma	2.24e-05	4.76e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—melanoma	2.24e-05	4.76e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—melanoma	2.24e-05	4.75e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—melanoma	2.23e-05	4.73e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—melanoma	2.22e-05	4.72e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—melanoma	2.22e-05	4.71e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—melanoma	2.22e-05	4.7e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—melanoma	2.21e-05	4.7e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK1—melanoma	2.21e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FGF2—melanoma	2.21e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—melanoma	2.21e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK1—melanoma	2.21e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—melanoma	2.21e-05	4.69e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—melanoma	2.2e-05	4.66e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK1—melanoma	2.19e-05	4.66e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—melanoma	2.19e-05	4.65e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1B—melanoma	2.19e-05	4.64e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1B—melanoma	2.18e-05	4.62e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—melanoma	2.16e-05	4.59e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—melanoma	2.15e-05	4.57e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK1—melanoma	2.15e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—melanoma	2.15e-05	4.56e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—melanoma	2.14e-05	4.55e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2—melanoma	2.14e-05	4.54e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—melanoma	2.13e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—melanoma	2.13e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2—melanoma	2.13e-05	4.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK3—melanoma	2.12e-05	4.5e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—melanoma	2.12e-05	4.49e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—melanoma	2.09e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—melanoma	2.09e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—melanoma	2.09e-05	4.43e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—melanoma	2.08e-05	4.41e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—melanoma	2.08e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—melanoma	2.07e-05	4.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—melanoma	2.07e-05	4.39e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CTNNB1—melanoma	2.07e-05	4.38e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—melanoma	2.06e-05	4.38e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CTNNB1—melanoma	2.06e-05	4.36e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ERBB2—melanoma	2.04e-05	4.33e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—melanoma	2.03e-05	4.31e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—melanoma	2.03e-05	4.3e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK1—melanoma	2.02e-05	4.28e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—melanoma	2.02e-05	4.28e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1A—melanoma	2.02e-05	4.28e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—melanoma	2.02e-05	4.27e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—melanoma	2.01e-05	4.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—melanoma	2.01e-05	4.27e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1A—melanoma	2.01e-05	4.26e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NFKB1—melanoma	2e-05	4.25e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—melanoma	2e-05	4.25e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NFKB1—melanoma	1.99e-05	4.23e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—melanoma	1.96e-05	4.17e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—melanoma	1.95e-05	4.15e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—melanoma	1.93e-05	4.1e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—melanoma	1.92e-05	4.08e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—melanoma	1.92e-05	4.07e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—melanoma	1.92e-05	4.07e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—melanoma	1.91e-05	4.04e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—melanoma	1.9e-05	4.04e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1B—melanoma	1.89e-05	4.01e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—melanoma	1.87e-05	3.96e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—melanoma	1.86e-05	3.96e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—melanoma	1.86e-05	3.94e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—melanoma	1.85e-05	3.93e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—melanoma	1.85e-05	3.93e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2—melanoma	1.85e-05	3.92e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—melanoma	1.84e-05	3.91e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—melanoma	1.84e-05	3.9e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—melanoma	1.82e-05	3.86e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—melanoma	1.81e-05	3.84e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—melanoma	1.8e-05	3.83e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—melanoma	1.8e-05	3.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—melanoma	1.8e-05	3.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—melanoma	1.8e-05	3.81e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—melanoma	1.79e-05	3.8e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—melanoma	1.79e-05	3.79e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CTNNB1—melanoma	1.78e-05	3.79e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—melanoma	1.78e-05	3.77e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—melanoma	1.77e-05	3.76e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—melanoma	1.76e-05	3.74e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—melanoma	1.75e-05	3.72e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—melanoma	1.75e-05	3.71e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1A—melanoma	1.74e-05	3.7e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—melanoma	1.74e-05	3.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NFKB1—melanoma	1.73e-05	3.67e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—melanoma	1.73e-05	3.66e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK3—melanoma	1.72e-05	3.65e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK3—melanoma	1.71e-05	3.63e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—melanoma	1.7e-05	3.6e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—melanoma	1.7e-05	3.6e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—melanoma	1.7e-05	3.6e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—melanoma	1.69e-05	3.59e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—melanoma	1.69e-05	3.58e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—melanoma	1.67e-05	3.55e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—melanoma	1.66e-05	3.53e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—melanoma	1.65e-05	3.5e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK1—melanoma	1.64e-05	3.47e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—melanoma	1.64e-05	3.47e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK1—melanoma	1.63e-05	3.45e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—melanoma	1.63e-05	3.45e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—melanoma	1.62e-05	3.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—melanoma	1.57e-05	3.33e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—melanoma	1.57e-05	3.33e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—melanoma	1.57e-05	3.32e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—melanoma	1.56e-05	3.3e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—melanoma	1.56e-05	3.3e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—melanoma	1.55e-05	3.29e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—melanoma	1.55e-05	3.29e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—melanoma	1.55e-05	3.28e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—melanoma	1.54e-05	3.26e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—melanoma	1.52e-05	3.23e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK3—melanoma	1.49e-05	3.15e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—melanoma	1.45e-05	3.07e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—melanoma	1.43e-05	3.04e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—melanoma	1.42e-05	3.01e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK1—melanoma	1.41e-05	3e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—melanoma	1.41e-05	3e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—melanoma	1.41e-05	3e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—melanoma	1.37e-05	2.92e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—melanoma	1.37e-05	2.9e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—melanoma	1.34e-05	2.83e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—melanoma	1.31e-05	2.79e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—melanoma	1.31e-05	2.77e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—melanoma	1.26e-05	2.67e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—melanoma	1.25e-05	2.65e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—melanoma	1.23e-05	2.6e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—melanoma	1.19e-05	2.52e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—melanoma	1.16e-05	2.46e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—melanoma	1.15e-05	2.45e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—melanoma	1.14e-05	2.41e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—melanoma	1.09e-05	2.31e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—melanoma	1e-05	2.13e-05	CbGpPWpGaD
